CB
CBL.AU Control Bionics Ltd
- Market cap
- AUD 28.3M
- P/E
- -
- P/B
- 4.48x
- ROE
- -231.7%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CBL.AU undervalued?
Graham numberThe Graham number of Control Bionics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Control Bionics Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-231.7%), below 10%.
ROA 0/1
Return on assets (-161.7%) is below the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (15.4%) is below the industry median (24.9%).
Revenue Growth 0/2
Revenue shrank 5.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (9.8%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (4.5x) is above the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Control Bionics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. T…
Full company profileControl Bionics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Control Bionics Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 311M | 805K | 781K | 3.10M | 4.09M | 4.50M | 5.64M | 5.35M | 6.14M | 4.77M | 7.79M |
| Gross Profit | 311M | -285K | -634K | 216K | 2.50M | -2.91M | 3.71M | 3.90M | 4.11M | -4.14M | -7.86M |
| Operating Income | 54.9M | -1.06M | -2.05M | -1.20M | -2.95M | -6.01M | -5.21M | -5.93M | -5.83M | -7.29M | -15.3M |
| EBITDA | 61.2M | -1.05M | -2.04M | -990K | -3.40M | -6.01M | -5.14M | -5.01M | -4.97M | -7.29M | -15.3M |
| Net Income | 28.6M | -972K | -1.93M | -1.01M | -3.55M | -6.11M | -5.63M | -5.91M | -6.11M | -7.27M | -14.6M |
| EPS | 0.13 | -0.01 | -0.02 | -0.01 | -0.04 | -0.06 | -0.06 | -0.04 | -0.02 | -0.02 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.16B | 6.31M | 5.43M | 20.5M | 18.4M | 13.4M | 8.70M | 9.03M | 8.23M | 9.05M | 9.05M |
| Total Liabilities | 876M | 216K | 376K | 387K | 1.19M | 1.51M | 1.58M | 2.76M | 2.72M | 2.73M | 2.73M |
| Shareholders' Equity | 281M | 6.09M | 5.05M | 20.1M | 17.2M | 11.9M | 7.15M | 6.27M | 5.51M | 6.31M | 6.31M |
| Cash & Short-term Investments | 396M | 1.84M | 799K | 15.6M | 12.3M | 5.21M | 936K | 981K | 673K | 2.08M | 2.08M |
| Total Debt | 38.5M | - | - | 282K | 14.9K | 285K | 129K | 962K | 435K | 619K | 619K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -971K | -1.95M | -864K | -3.99M | -6.89M | -4.53M | -4.91M | -4.27M | -5.75M | -14.1M |
| Capital Expenditure | 3.05M | 14.3K | 35.6K | 302K | 53.4K | 148K | 458K | 473K | 302K | 10.0K | 600K |
| Free Cash Flow | -3.05M | -985K | -1.98M | -1.17M | -4.04M | -5.75M | -4.98M | -5.38M | -4.57M | -5.76M | -13.5M |
| Ratios | |||||||||||
| ROE | 10.2% | -16.0% | -38.2% | -5.0% | -20.7% | -51.2% | -78.8% | -94.4% | -110.9% | -115.1% | -231.7% |
| ROA | 2.5% | -15.4% | -35.6% | -4.9% | -19.3% | -45.5% | -64.8% | -65.5% | -74.2% | -80.3% | -161.7% |
| Net Profit Margin | 9.2% | -120.7% | -247.2% | -32.4% | -86.8% | -135.7% | -99.8% | -110.5% | -99.4% | -152.4% | -187.8% |
| Debt to Equity | 0.14x | - | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.15x | 0.08x | 0.10x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Control Bionics Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | AUD 48.5K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Control Bionics Ltd
- Insiders 44.58%
- Institutions 20.20%
- Public & others 35.22%
- Shares outstanding 544M
- Free float 214M
Control Bionics Ltd company profile
- Company name
- Control Bionics Ltd
- Ticker
- CBL.AU
- ISIN
- AU0000114183
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 11-13 Pearson Street, Cremorne, VIC, Australia, 3121
- Phone
- 61 3 9897 3576
- Website
- controlbionics.com
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
Control Bionics Ltd management
6- Mr. Jeremy E. Steele B.Com.CEO, MD & Executive Director
- Ms. Shannon BoothroydChief Financial Officer
- Mr. Todd TylerPresident of North America
- Prof. Nicholas Opie B.E., B.Sc., M.B.A., Ph.D.Non-Executive Director & Strategic Advisor
- Mr. James SchoreyChief Technology Officer
- Mr. Brett Thomas Crowley B.Com., C.A., DipLawCompany Secretary · born 1957